These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 1634193)

  • 1. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy.
    Greco AV; Caputo S; Bertoli A; Ghirlanda G
    Horm Metab Res; 1992 Jun; 24(6):280-3. PubMed ID: 1634193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes.
    Sinagra D; Scarpitta AM; Amato M
    Eur Rev Med Pharmacol Sci; 1998; 2(5-6):175-9. PubMed ID: 10710815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus.
    Rattarasarn C; Thamprasit A; Leelawattana R; Soonthornpun S; Setasuban W
    J Med Assoc Thai; 2001 Dec; 84(12):1754-62. PubMed ID: 11999824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of combination therapy with insulin and oral hypoglycemic agents in patients with type II diabetes during a 1-year period.
    Mozersky RP; Patel H; Bahl VK; Bahl S; Mook W
    J Am Osteopath Assoc; 1996 Jun; 96(6):346-51. PubMed ID: 8690621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs.
    Mohan V; Snehalatha C; Ramachandran A; Viswanathan M
    J Assoc Physicians India; 1990 Aug; 38(8):537-41. PubMed ID: 2123183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).
    Zhou Z; Li X; Huang G; Peng J; Yang L; Yan X; Wang J
    Diabetes Metab Res Rev; 2005; 21(2):203-8. PubMed ID: 15386806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.
    Levy J; Atkinson AB; Bell PM; McCance DR; Hadden DR
    Diabet Med; 1998 Apr; 15(4):290-6. PubMed ID: 9585393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta cell function in long term NIDDM (type 2) patients and its relation to treatment.
    Snehalatha C; Ramachandran A; Mohan V; Timothy H; Viswanathan M
    Horm Metab Res; 1986 Jun; 18(6):391-4. PubMed ID: 3525362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in Diabetes mellitus.
    Irvine WJ; Sawers JS; Feek CM; Prescott RJ; Duncan LJ
    J Clin Lab Immunol; 1979 Apr; 2(1):23-6. PubMed ID: 95802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease.
    Pontiroli AE; Calderara A; Pacchioni M; Cassisa C; Pozza G
    Diabete Metab; 1993; 19(1):30-5. PubMed ID: 8504882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic beta cell response in insulin treated NIDDM patients limitations of a random C-peptide measurement.
    Snehalatha C; Ramachandran A; Mohan V; Viswanathan M
    Diabete Metab; 1987 Feb; 13(1):27-30. PubMed ID: 3552773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of insulin therapy on non-insulin-dependent diabetics with secondary oral hypoglycemic agent failure.
    Peng YS; Juang JH
    Changgeng Yi Xue Za Zhi; 1998 Sep; 21(3):271-6. PubMed ID: 9849007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release.
    Pontiroli AE; Calderara A; Maffi P; Bonisolli L; Carenini A; Piatti PM; Monti LD; Gallus G; Pozza G; Illeni MT
    Diabete Metab; 1989; 15(2):79-84. PubMed ID: 2661281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide.
    Trischitta V; Italia S; Borzi V; Tribulato A; Mazzarino S; Squatrito S; Vigneri R
    Diabetes Care; 1989 Sep; 12(8):582-5. PubMed ID: 2505990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-obese adult onset diabetes with oral hypoglycemic agent failure: islet cell autoantibodies or reversible beta cell refractoriness?
    Sá JR; Silva RC; Nasri F; Aguade LC; Velloso L; Chacra AR; Dib SA
    Braz J Med Biol Res; 2003 Oct; 36(10):1301-9. PubMed ID: 14502361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedtime intermediate-acting insulin in the treatment of secondary failure to oral hypoglycemic agents.
    Chuang LM; Lu C; Su RJ; Wu HP; Tai TY; Lin BJ
    J Formos Med Assoc; 1992 Feb; 91(2):185-9. PubMed ID: 1364216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.